Hepatic Encephalopathy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Hepatic Encephalopathy - Pipeline Review, H2 2016

Hepatic Encephalopathy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Hepatic Encephalopathy - Pipeline Review, H2 2016
Published Jul 13, 2016
64 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hepatic Encephalopathy - Pipeline Review, H2 2016, provides an overview of the Hepatic Encephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy
- The report reviews pipeline therapeutics for Hepatic Encephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hepatic Encephalopathy therapeutics and enlists all their major and minor projects
- The report assesses Hepatic Encephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hepatic Encephalopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatic E

  
Source:
Document ID
GMDHC8227IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Hepatic Encephalopathy Overview71
Therapeutics Development81
  Pipeline Products for Hepatic Encephalopathy Overview81
Hepatic Encephalopathy Therapeutics under Development by Companies91
Hepatic Encephalopathy Pipeline Products Glance104
  Late Stage Products101
  Clinical Stage Products111
  Early Stage Products121
  Unknown Stage Products131
Hepatic Encephalopathy Products under Development by Companies141
Hepatic Encephalopathy Companies Involved in Therapeutics Development158
  Alfa Wassermann S.p.A151
  Cosmo Pharmaceuticals S.p.A161
  Horizon Pharma Plc171
  KannaLife Sciences, Inc.181
  Ocera Therapeutics, Inc.191
  Rebiotix Inc.201
  Spherium Biomed S.L.211
  Umecrine Cognition AB221
Hepatic Encephalopathy Therapeutics Assessment239
  Assessment by Monotherapy Products231
  Assessment by Target242
  Assessment by Mechanism of Action262
  Assessment by Route of Administration282
  Assessment by Molecule Type302
Drug Profiles3220
  glycerol phenylbutyrate Drug Profile325
  GR-3027 Drug Profile371
  KLS-13019 Drug Profile381
  ornithine phenylacetate Drug Profile395
  RBX-2477 Drug Profile441
  rifamycin CR Drug Profile452
  rifaximin Drug Profile474
  THDP-17 Drug Profile511
Hepatic Encephalopathy Dormant Projects521
Hepatic Encephalopathy Product Development Milestones5310
  Featured News &Press Releases531
    Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL)531
    Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology541
    Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy541
    Dec 09, 2015: Umecrine Cognition Announces Grant Of a US Patent Protecting Its Lead Candidate Drug GR3027551
    Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy561
    Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy571
    Aug 19, 2015: Umecrine Cognition announces the publication of preclinical results of the candidate drug GR3027 aimed for the treatment of hepatic encephalopathy581
    Aug 11, 2015: Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019581
    Apr 20, 2015: Lupin Launches Zaxine in Canada591
    Apr 01, 2015: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy591
    Sep 18, 2014: Salix Secures Additional Intellectual Property Relating to Rifaximin601
    Sep 12, 2014: Lupin and Salix Announce Exclusive Distribution Agreement for Zaxine in Canada601
    Feb 25, 2014: Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate for the Treatment of Hepatic Encephalopathy in Hepatology611
    Feb 14, 2014: Luxembourg National Health Fund Approves Reimbursement Of Xifaxan 550611
    Feb 04, 2014: Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin621
Appendix632
  Methodology631
  Coverage631
  Secondary Research631
  Primary Research631
  Expert Panel Validation631
  Contact Us631
  Disclaimer641

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hepatic Encephalopathy - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hepatic-Encephalopathy-Pipeline-Review-H2-2016-2088-16161>
  
APA:
Global Markets Direct - Market Research. (2016). Hepatic Encephalopathy - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hepatic-Encephalopathy-Pipeline-Review-H2-2016-2088-16161>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.